Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00910897
Recruitment Status : Unknown
Verified May 2009 by Intergroupe Francophone du Myelome.
Recruitment status was:  Active, not recruiting
First Posted : June 1, 2009
Last Update Posted : June 1, 2009
Information provided by:
Intergroupe Francophone du Myelome

Brief Summary:

Primary objective:

  • Compare the complete remission (CR) rates (i.e., the true CR, with negative immunofixation) achieved with either four courses of VD or four courses of VTD.

Secondary objectives:

  • Compare the following parameters following 4 cycles of VD or VTD induction treatment:

    • CR rate+ very good partial remission (VGPR) rate
    • Overall remission rate (CR + VGPR + partial remission (PR) rate)
    • K/l light chain ratio in patients in CR.
    • Safety (quality of the sampled stem cells, extrahaematological and haematological toxicity: specially neurological toxicity, length of hospitalization).
  • Compare the CR rate and the CR + VGPR rates after post-induction autologous stem cell transplantation (ASCT).

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Velcade-Dexamethasone Drug: Velcade-Thalidomide-Dexamethasone Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 205 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Study Start Date : March 2008
Estimated Primary Completion Date : August 2009

Arm Intervention/treatment
Active Comparator: Velcade-Dexamethasone Drug: Velcade-Dexamethasone
Active Comparator: Velcade-Thalidomide-Dexamethasone Drug: Velcade-Thalidomide-Dexamethasone

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Newly diagnosed symptomatic multiple myeloma (MM) patient
  • Aged under 65
  • Candidate for ASCT, with measurable levels of paraprotein in the serum (³ 10 g/L) or the urine (³ 200 mg/day)
  • Using effective contraceptive methods (for fertile men, women of childbearing potential)
  • Provision of informed consent
  • No evidence of active infection

Exclusion Criteria:

  • Asymptomatic MM
  • Non-secretory MM
  • Aged 66 years or over
  • ECOG performance status over 2 (see Appendix 2)
  • Proven amyloidosis
  • A personal medical history of cancer (except for basocellular skin cancer or in situ cervical cancer)
  • Positive HIV serology
  • A personal medical history of severe psychiatric disease
  • Severe diabetes contraindicating the use of high-dose dexamethasone
  • NCI grade ³ 2 peripheral neuropathy
  • Serum clinical chemistry:

    • creatinine level > 300 µmol/L or requiring dialysis
    • bilirubin, transaminases or GamaGT > 3 the upper normal limit (UNL)
  • Prior or current systemic therapy for MM, including steroids (except for emergency use of a 4-day block of dexamethasone between the screening phase and randomization)
  • Radiation therapy in the 2 weeks preceding randomization
  • A personal medical history of allergic reactions to compounds containing boron or mannitol
  • Non-controlled or severe cardiovascular disease (including a myocardial infarction in the 6 months prior to recruitment) or NYHA class III or IV renal failure
  • Use of any investigational drug in the 30 days preceding randomization
  • Pregnant or lactating women; a serum Beta-hCG pregnancy test must be performed during the screening phase for female patients of childbearing potential
  • Severe pulmonary troubles (including acute infiltrative pneumopathy)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00910897

  Show 56 Study Locations
Sponsors and Collaborators
Intergroupe Francophone du Myelome

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Principal investigator: HAROUSSEAU Jean-Luc, University Hospital, Nantes Identifier: NCT00910897     History of Changes
Other Study ID Numbers: IFM 2007-02
Eudract 2007-005204-40
First Posted: June 1, 2009    Key Record Dates
Last Update Posted: June 1, 2009
Last Verified: May 2009

Keywords provided by Intergroupe Francophone du Myelome:
Newly Diagnosed
multiple myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents